Literature DB >> 17387481

[Topical immunosuppressives after penetrating keratoplasty].

F Birnbaum1, A Reis, T Reinhard.   

Abstract

Topical steroids are routinely used in the postoperative treatment following penetrating keratoplasty. Due to the known side effects such as steroid-response glaucoma, cataract, and surface disorders, a broader armamentarium of topical immunomodulating drugs with comparable efficacy, better tolerance and less side effects is desirable. Cyclosporine A and FK506 eye drops are a promising alternative. A new approach involves subconjunctival drug delivering implants and locally applied antiangiogenic substances, which still have to be tested in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387481     DOI: 10.1007/s00347-007-1516-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  42 in total

Review 1.  Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology.

Authors:  Claus Cursiefen; Lu Chen; M Reza Dana; J Wayne Streilein
Journal:  Cornea       Date:  2003-04       Impact factor: 2.651

2.  Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats.

Authors:  K Okada; H Sakata; A Minamoto; M Fujihara
Journal:  Ophthalmologica       Date:  1996       Impact factor: 3.250

Review 3.  Mycophenolate mofetil and its mechanisms of action.

Authors:  A C Allison; E M Eugui
Journal:  Immunopharmacology       Date:  2000-05

4.  Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty.

Authors:  C Cursiefen; H Wenkel; P Martus; A Langenbucher; N X Nguyen; B Seitz; M Küchle; G O Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-07       Impact factor: 3.117

5.  [Regression analysis of idiopathic endothelial cell loss after perforating normal risk keratoplasty: basic principles for long-term analysis of endothelial risk factors in a retrospective clinical study].

Authors:  D Böhringer; T Reinhard; E Godehardt; R Sundmacher
Journal:  Klin Monbl Augenheilkd       Date:  2001-06       Impact factor: 0.700

6.  Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty.

Authors:  K Inoue; S Amano; C Kimura; T Sato; N Fujita; F Kagaya; Y Kaji; T Oshika; T Tsuru; M Araie
Journal:  Jpn J Ophthalmol       Date:  2000 May-Jun       Impact factor: 2.447

7.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

Authors:  K Sall; O D Stevenson; T K Mundorf; B L Reis
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

8.  FK-506 delays corneal graft rejection in a model of corneal xenotransplantation.

Authors:  U Benelli; A Lepri; M Del Tacca; M Nardi
Journal:  J Ocul Pharmacol Ther       Date:  1996       Impact factor: 2.671

9.  Long-term results of allogeneic penetrating limbo-keratoplasty in total limbal stem cell deficiency.

Authors:  Thomas Reinhard; Helga Spelsberg; Lotte Henke; Theodoros Kontopoulos; Jürgen Enczmann; Peter Wernet; Peter Berschick; Rainer Sundmacher; Daniel Böhringer
Journal:  Ophthalmology       Date:  2004-04       Impact factor: 12.079

10.  Topical cyclosporine in pediatric keratoplasty.

Authors:  C Banu Cosar; Peter R Laibson; Elisabeth J Cohen; Christopher J Rapuano
Journal:  Eye Contact Lens       Date:  2003-04       Impact factor: 2.018

View more
  2 in total

Review 1.  [Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation].

Authors:  T Lapp; P Maier; F Birnbaum; G Schlunck; T Reinhard
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

2.  Topical pimecrolimus does not prolong clear graft survival in a rat keratoplasty model.

Authors:  Florian Birnbaum; Johannes Schwartzkopff; Christoph Scholz; Thomas Reinhard
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-21       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.